The author of 《I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo》 were Jia, Panli; Wu, Yao; Du, Hongzhi; Yang, Lijun; Zhang, Zhibo; Ma, Tianfang; Li, Sun; Yuan, Shengtao; Lu, Ligong; Zha, Xiaoming. And the article was published in European Journal of Pharmaceutical Sciences in 2019. Application In Synthesis of 2,4-Dichloropyrimidine The author mentioned the following in the article:
Isocitrate dehydrogenase 1 mutations have been discovered in an array of hematol. malignancies and solid tumors. These mutations could cause the production of high levels of 2-hydroxyglutarate, which in turn implicated in epigenetic changes and impaired cell differentiation. Here, we described the characterization of compound I-8, a novel mutant IDH1 inhibitor, both in vitro and in vivo. Compound I-8 specifically inhibited 2-HG production, reduced histone methylation levels, induced differentiation and depleted stem characteristics in engineered and endogenous IDH1 mutant cells. In addition, oral administration of I-8 also significantly suppressed 2-HG production and histone methylation with dose of 150 mg/kg. And I-8 treatment also could induce differentiation and attenuate stem characteristics in tumor tissue. Together, these studies indicated that compound I-8 has clin. potential in tumor therapies as a effective mutant IDH1 inhibitor, and provided scientific guidance for the development of mutant IDH1 inhibitor in the future. In addition to this study using 2,4-Dichloropyrimidine, there are many other studies that have used 2,4-Dichloropyrimidine(cas: 3934-20-1Application In Synthesis of 2,4-Dichloropyrimidine) was used in this study.
2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Organic chloride content in crude oil can be detected through specialized laboratory analysis. Care and attention are essential while sampling and testing.Application In Synthesis of 2,4-Dichloropyrimidine
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia